|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/00 |
| (11) | Number of the document | 3035956 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14837376.4 |
| Date of filing the European patent application | 2014-08-20 | |
| (97) | Date of publication of the European application | 2016-06-29 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/051793 |
| Date | 2014-08-20 |
| (87) | Number | WO 2015/026894 |
| Date | 2015-02-26 |
| (30) | Number | Date | Country code |
| 201361869528 P | 2013-08-23 | US | |
| 201361907691 P | 2013-11-22 | US | |
| 13198859 | 2013-12-20 | EP |
| (72) |
MOORE, Paul A., US
LI, Jonathan, US
CHEN, Francine Zhifen, US
JOHNSON, Leslie S., US
SHAH, Kalpana, US
BONVINI, Ezio, US
|
| (73) |
MacroGenics, Inc.,
9704 Medical Center Drive, Rockville, MD 20850,
US
|
| (54) | BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF |
| BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF |